DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel

References

• Au W, Salama S, Sierra-Torres C. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Env Hlth Persp 2003; 111: 1843–1850
   PubMed Web of Science ®Google Scholar
• Cadet J, Weingeld M. Detecting DNA damage. Analyt Chem 1993; 65: 675–682
   PubMed Web of Science ®Google Scholar
• Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 2003; 170: 2471–2474
   PubMed Web of Science ®Google Scholar
• Cho EY, Hildesheim A, Chen CJ, Hsu MM, Chen IH, Mittl BF, Levine BH, Liu MY, Chen JY. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epid Biom Prev 2003; 12: 1100–1104
   PubMed Web of Science ®Google Scholar
• Dherin C, Radicella J, Dizdaroglu M, Boiteux S. Excision of oxidatively damaged DNA bases by the human α-hOGG1 protein and the polymorphic α-hOGG1(Ser326Cys) protein which is frequently found in human populations. Nucl Acids Res 1999; 27: 4001–4007
   PubMed Web of Science ®Google Scholar
• Frebourg T, Friend SH. Cancer risks from germ line p53 mutations. J Clin Invest 1992; 90: 1637–1641
   PubMed Web of Science ®Google Scholar
• Fukunaga-Takenaka R, Fukunaga K, Tatemichi M, Ohshima H. Nitric oxide prevents UV-induced phosphorylation of the p53 tumour-suppressor protein at serine 46: a possible role in inhibition of apoptosis. Biochem Biophys Res Comm 2003; 308: 966–974
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Biondi M, Cecchini F, DeMonti M, Guagnellini E. Vascular invasions in human breast cancer are correlated to T→786C polymorphism of NOS3 gene. Nitric Oxide 2003; 9: 118–122
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Biondi M, DeMonti M, Bernini M, Turri O, Farilla S, Versari D, Sudano I, Dessina AC, Salvetti A. Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthetase gene. Clin Chem 2002; 48: 989–993
   PubMed Web of Science ®Google Scholar
• Goode E, Ulrich C, Potter J. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epid Biom Prev 2002; 11: 1513–1530
   PubMed Web of Science ®Google Scholar
• Hou SM, Ryk C, Kannio A, Angelini S, Fält S, Nyberg F, Husgafval-Pursiainen K. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumours. Environ Mol Mutagen 2003; 41: 37–42
   PubMed Web of Science ®Google Scholar
• Janssen K, Schlink K, Gotte W, Hippler B, Kaina B, Oesch F. DNA repair activity of 8-oxoguanine DNA glycosylase I (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res 2001; 486: 207–216
   PubMedGoogle Scholar
• Kohno T, Shinmura K, Tosaka M, Tani M, Kim S, Sugimura H, Nohmi T, Kasai H, Yokota J. Genetic polymorphisms and alternative splicing of the hOOG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1988; 16: 3219–3225
   Google Scholar
• Kondo S, Satoh Y, Kuroki T. Reduced levels of UV-induced unscheduled DNA synthesis in epidermal keratinocytes of patients with xeroderma pigmentosum and correlation with development of skin neoplasms. Cancer Res 1989; 49: 1927–1930
   PubMed Web of Science ®Google Scholar
• Li Y, Marion MJ, Rundle A, Brandt-Rauf P. A common polymorphism in XRCC1 as a biomarker of susceptibility for chemically induced genetic damage. Biomarkers 2003; 8: 408–414
   PubMed Web of Science ®Google Scholar
• Marin M, Jost C, Brooks L, Irwin M, O'Nions J. A common polymorphism acts as an intragenic modifier of p53 behaviour. Nature Genet 2000; 25: 47–54
   PubMed Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumour cell lines. J Natl Cancer Inst 1991; 83: 757–766
   PubMed Web of Science ®Google Scholar
• O'Connor PM, Jackman J, Bae I, Myers TG, Fan S. Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285–4300
   PubMed Web of Science ®Google Scholar
• Papadakis E, Soulitzis N, Spandidos D. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 2002; 87: 1013–1018
   PubMed Web of Science ®Google Scholar
• Roschke AV, Tonon G, Gelhaus KS, McTyre N, Bussey KJ, Weinstein JN, Kirsch IR. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003; 63: 8634–8647
   PubMed Web of Science ®Google Scholar
• Rossi G, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, Versari D, Sudano I, Pessina AC, Salvetti A. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Col Cardiol 2003; 41: 938–945
   PubMed Web of Science ®Google Scholar
• Rybicki B, Conti D, Moreira A, Cicek M, Casey G, Witte JS. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epid Biom Prev 2004; 13: 23–29
   PubMed Web of Science ®Google Scholar
• Song J, Yoon Y, Park K, Park J, Hong Y, Hong SH, Kim JO. Genotype-specific influence on nitric oxide synthetase gene expression, protein concentrations, and enzyme activity in cultured human endothelial cells. Clin Chem 2003; 49: 847–852
   PubMed Web of Science ®Google Scholar
• Tang D, Cho S, Rundle A, Chen S, Phillips D, Zhou J, Hsu Y, Schnabel F, Estabrook A, Perera FP. Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treat 2002; 75: 159–166
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler K. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Wang Y, Spitz M, Zhou Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair 2003; 2: 901–908
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubenstein LV. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343–349
   PubMed Web of Science ®Google Scholar
• Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA. DNA repair protein levels vis-à-vis anticancer durg resistance in the human tumour cell lines of the National Cancer Institute drug screening program. Anti-Cancer Drugs 2002; 13: 511–519
   PubMed Web of Science ®Google Scholar